These results, in addition to revealing the relevance of ERK5 in TNBC, open the door to the clinical evaluation of TG02 in the breast cancer clinic, especially in combination with standard- of-care chemotherapies used in the treatment of TNBC. This evidence concerns the gene MAPK7 and breast cancer.